Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2009
10/20/2009US7605157 Tricyclic tetrahydroquinoline antibacterial agents
10/20/2009US7605156 4-{3-[1-benzhydryl-5-chloro-2-(2-{[(2,6-dimethylbenzyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid; asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke
10/20/2009US7605155 Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors; cyclin dependent kinases (CDKs) inhibitors; cancer, inflammation and arthritis; neurodegenerative diseases such Alzheimer's; cardiovascular, viral and fungal diseases
10/20/2009US7605154 Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
10/20/2009US7605153 Use of paullone derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells
10/20/2009US7605152 such as 16 alpha -fluoro-17 beta -hydroxy-4-methyl-4-aza-5 alpha -androst-1-en-3-one, used for hormone replacement therapy
10/20/2009US7605151 Nitrate esters of corticoid compounds and pharmaceutical applications thereof
10/20/2009US7605150 Drug therapy for Celiac Sprue
10/20/2009US7605149 Modulation of the phospholipase A2 pathway as a therapeutic
10/20/2009US7605148 Aqueous oral solution of bisphosphonic acid
10/20/2009US7605147 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
10/20/2009US7605145 Prevents organ damage
10/20/2009US7605144 Proliferation inhibition of pathological cells; prodrug converted to or releasing cellular toxin
10/20/2009US7605143 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
10/20/2009US7605141 Preserving vitamins subject to oxidative damage by adding a sufficient amount of purified nucleic acid to vitamin such that the rate of oxidative damage of the vitamin is reduced
10/20/2009US7605139 Genes encoding Mycobacterium bovis bacillus Calmette-Guerin (M. bovis BCG) recombinant antigens and those for interleukin-12 heterodimer were respectively cloned into eukaryotic expression vectors; attenuating or suppressing the growth of bladder cancer cells
10/20/2009US7605138 Nucleic acid compositions for stimulating immune responses
10/20/2009US7605137 1,2-Bis-(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)-hydrazine (Cloretazine(TM), laromustine) and cytarabine; inhibiting tumor cell growth; cancer
10/20/2009US7605136 Epothilone - saccharide complex; antiproliferative agents; antitumor agents; antiinflammatory agents; central nervous system disorders; multiple sclerosis; Alzheimer's disease; rheumatic disorders; antiarthritic agents
10/20/2009US7605135 Baicalin as a treatment for SARS infection
10/20/2009US7605134 Pesticides
10/20/2009US7605124 an ejection liquid for stably ejecting a solution containing at least one kind of insulin ( polyoxyethylene glycol or polyvinyl alcohol modified insulin), citric acid and a surfactant; ejecting the liquid by a thermal inkjet system
10/20/2009US7605119 Administering an atypical form of protein kinase C, such as PKM zeta or PKC iota/lambda; also treating brain and spinal cord injuries
10/20/2009US7604968 Microorganisms for the recombinant production of resveratrol and other flavonoids
10/20/2009US7604958 Transfection, culturing; electrophoresis
10/20/2009US7604949 For skin lightening or darkening; cell-free; drug screening
10/20/2009US7604821 Fresh water sponge with excipient
10/20/2009US7604812 For the treatment of dry, sensitive skin. Despite being free from such ingredients as perfumes, preservatives, colorings, plant extracts, PEGs, cetylstearyl alcohol, lanolin alcohol, lower alcohols and proteins
10/20/2009US7604804 Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120
10/20/2009US7604797 Compositions and methods for treating burns
10/20/2009CA2585898C Use of (2s,3s,5s)-5-(n-(n-((n-methyl-n-((2-isopropyl-4-thaizolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(n-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane in combination with another protease inhibitor for treating hiv infection
10/20/2009CA2537373C Selective synthesis of cf3-substituted pyrimidines
10/20/2009CA2532925C Azolo triazines and pyrimidines
10/20/2009CA2527093C 3-fluoro-piperidines as nmda/nr2b antagonists
10/20/2009CA2520898C Non-cross-linking pyrrolo(2,1-c)(1,4)benzodiazepines as potential antitumour agents and process thereof
10/20/2009CA2492854C Sustained-release tablet composition of pramipexole
10/20/2009CA2469821C Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
10/20/2009CA2456127C Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
10/20/2009CA2450122C Novel heterocyclic antibacterial compounds
10/20/2009CA2446712C System for osmotic delivery of pharmaceutically active agents
10/20/2009CA2441798C Crystalline isoxazole derivative and medical preparation thereof
10/20/2009CA2427762C Process for the preparation of crystalline n-formimidoyl thienamycin monohydrate (imipenem monohydrate)
10/20/2009CA2423454C Estrogen-linked platinum (ii) complexes as anticancer agents
10/20/2009CA2408142C Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
10/20/2009CA2407371C Quinazoline derivatives for the treatment of tumours
10/20/2009CA2402267C Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails
10/20/2009CA2397591C Semi-synthetic taxanes with antitumor and antiangiogenetic activities
10/20/2009CA2393303C Meglumine salt of a specific quinolinecarboxylic acid compound
10/20/2009CA2389349C Aerosol composition comprising formoterol
10/20/2009CA2385130C Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
10/20/2009CA2380986C Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions
10/20/2009CA2380852C Tricyclic compounds having spiro union
10/20/2009CA2379329C Oral treatment of companion animals with ectoparasiticidal spinosyns
10/20/2009CA2379294C Process for preparing dibenzothiazepine derivatives
10/20/2009CA2378428C Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
10/20/2009CA2378183C Antibacterial heterobicyclic substituted phenyl oxazolidinones
10/20/2009CA2376894C Pharmaceutical composition comprising a protein and an ectoine
10/20/2009CA2376226C New formulation
10/20/2009CA2368993C C7 ester substituted taxanes as antitumor agents
10/20/2009CA2368843C Neurotrophic substituted pyrimidines
10/20/2009CA2364662C 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
10/20/2009CA2358951C Reverse hydroxamate inhibitors of matrix metalloproteinases
10/20/2009CA2336909C Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity
10/20/2009CA2336663C Coumarin and related aromatic-based polymeric prodrugs
10/20/2009CA2330128C Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis
10/20/2009CA2314685C A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride
10/20/2009CA2306214C Plaster for topical use containing heparin and diclofenac
10/20/2009CA2287965C Treatment or prevention of menopausal symptoms and osteoporosis
10/20/2009CA2254116C Method and composition for the treatment of lipid and glucose metabolism disorders
10/20/2009CA2250085C Modulators of tnf receptor associated factor (traf), their preparation and use
10/20/2009CA2227467C Helper virus-free herpesvirus vector packaging system
10/20/2009CA2214793C Novel intermediates and process for the manufacture of camptothecin derivatives (cpt-11) and related compounds
10/20/2009CA2168937C Anti-neurodegeneratively active 10-aminoaliphatyl-dibenz[b,f]oxepines
10/20/2009CA2164717C Method of combatting hepatitis b virus infection
10/20/2009CA2126761C Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
10/18/2009CA2649477A1 Composition and method for promoting internal health and external appearance
10/15/2009WO2009126970A1 Method of assessing sensitivity to brostallicin
10/15/2009WO2009126949A1 Methods of administering prostratin and structural analogs thereof
10/15/2009WO2009126944A1 Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
10/15/2009WO2009126938A1 Nanoparticle formulations and uses thereof
10/15/2009WO2009126931A2 Combination therapy for bipolar disorder
10/15/2009WO2009126917A1 Method of providing hemostasis in anti-coagulated blood
10/15/2009WO2009126912A1 Compositions comprising n-halogenated or n, n-dihalogenated amine for treatment and prophylaxis of bronchopulmonary infections
10/15/2009WO2009126866A2 Delta-tocotrienol as a radioprotective countermeasure agent
10/15/2009WO2009126861A2 Triazolopyridine compounds useful as dgat1 inhibitors
10/15/2009WO2009126825A1 Steroid treatment for hot flashes
10/15/2009WO2009126822A2 Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
10/15/2009WO2009126806A2 Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
10/15/2009WO2009126805A2 Therapeutic tarageting of mmps in neutral liposomes
10/15/2009WO2009126764A1 Methods and use of inducing apoptosis in cancer cells
10/15/2009WO2009126743A1 Novel (pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases
10/15/2009WO2009126737A2 Triterpene saponins, methods of synthesis, and uses thereof
10/15/2009WO2009126726A1 Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
10/15/2009WO2009126705A2 Induction of tumor hypoxia for cancer therapy
10/15/2009WO2009126700A1 Hydroxylated tolans and related compounds as cosmetics or therapeutics for skin conditions
10/15/2009WO2009126695A2 Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
10/15/2009WO2009126691A1 Inhibitors of fatty acid amide hydrolase
10/15/2009WO2009126675A1 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10
10/15/2009WO2009126662A1 Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
10/15/2009WO2009126640A2 Compositions of modulators of the wnt/b-catenin pathway and an n-cinnamyl-n'-benzhydryl piperazine and their use in treating neoplastic conditions including malignant melanoma